Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
about
The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsMolecular pathways and therapeutic targets in lung cancerThe efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer.The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trialsTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials.Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trialsRisk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
P2860
Q33415118-DB06C6EF-8A21-4589-B50E-5F7917EDA0B5Q33438050-C4D74A6C-79BF-46B9-8F85-0309419A19BAQ33688872-C64171D0-28A7-4A71-A220-B16D67A42FA1Q35164824-1A59BECF-7696-4ED6-B3D0-84C505B94553Q35829916-E2939E1B-84EB-47BD-8A26-06FFBE895B95Q35899612-F983984E-282C-4C1A-BFA8-5CD92B2BAD6FQ36037036-A95F177E-9BE4-4845-BA8F-DAAE91CB1CC8Q36999705-7D184242-F32C-4312-A693-03CBF3159ECAQ37728603-B6973F9D-693E-4819-B52B-03941853AFAEQ38242086-A874B9E2-6AA8-4EAC-98E0-F1399A65096DQ38289406-A10BA3C7-ADBA-4044-ABF6-39107CA6EA58Q40403877-20A8D869-A0C9-41F8-833E-89724624EC52Q41130079-75582C2E-E681-431F-9814-35E4F08A7838Q42700668-A4417837-8FC7-4EE2-BEAF-101D5A609974Q51054919-6F860565-ABF5-4F2E-A6C6-24134E275845
P2860
Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Overall survival benefits for ...... ta-analysis of published data.
@ast
Overall survival benefits for ...... ta-analysis of published data.
@en
type
label
Overall survival benefits for ...... ta-analysis of published data.
@ast
Overall survival benefits for ...... ta-analysis of published data.
@en
prefLabel
Overall survival benefits for ...... ta-analysis of published data.
@ast
Overall survival benefits for ...... ta-analysis of published data.
@en
P2093
P2860
P1433
P1476
Overall survival benefits for ...... ta-analysis of published data.
@en
P2093
Da-Liu Min
Li-Na Tang
Qiong Wang
Yan-Ling Jiang
Yuan-Jue Sun
P2860
P304
P356
10.1371/JOURNAL.PONE.0055637
P407
P50
P577
2013-02-08T00:00:00Z